GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Return-on-Tangible-Asset

Bruker (Bruker) Return-on-Tangible-Asset : 26.08% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Bruker Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bruker's annualized Net Income for the quarter that ended in Dec. 2023 was $822 Mil. Bruker's average total tangible assets for the quarter that ended in Dec. 2023 was $3,152 Mil. Therefore, Bruker's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 26.08%.

The historical rank and industry rank for Bruker's Return-on-Tangible-Asset or its related term are showing as below:

BRKR' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.33   Med: 9.86   Max: 14.12
Current: 14.12

During the past 13 years, Bruker's highest Return-on-Tangible-Asset was 14.12%. The lowest was 3.33%. And the median was 9.86%.

BRKR's Return-on-Tangible-Asset is ranked better than
92.25% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -2.31 vs BRKR: 14.12

Bruker Return-on-Tangible-Asset Historical Data

The historical data trend for Bruker's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Return-on-Tangible-Asset Chart

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 6.65 9.90 9.92 13.74

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.85 10.51 7.69 11.81 26.08

Competitive Comparison of Bruker's Return-on-Tangible-Asset

For the Medical Devices subindustry, Bruker's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Bruker's Return-on-Tangible-Asset falls into.



Bruker Return-on-Tangible-Asset Calculation

Bruker's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=427.2/( (2883.3+3336.8)/ 2 )
=427.2/3110.05
=13.74 %

Bruker's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=822/( (2966.6+3336.8)/ 2 )
=822/3151.7
=26.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Bruker  (NAS:BRKR) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Bruker Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Bruker's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139